Table 2.

Demographics and clinical characteristics of patients according to the survival benefit from CIK cell therapy before and after use of PS weighting.

Clinicopathological variables	Original			PS weight
	Minimal survival benefit (n = 115)	Long-term survival benefit (n = 116)	p value	Minimal survival benefit (n = 83)	Long-term survival benefit (n = 83)	p value
Age (y)			0.626			0.377
Median	46	48		46	43
Range	25–80	14–70		28–77	14–70
Gender			0.640			0.393
Male	99	98		68	72
Female	18	21		15	11
Capsule			0.039			0.822
Complete	94	107		71	72
Incomplete	23	12		12	11
Tumor size (cm)			0.008			0.347
≤5	38	59		33	39
>5	79	60		50	44
TNM stage			<0.001			0.791
I	54	84		51	55
II	12	15		10	8
III	51	20		22	20
Tumor number			0.006			0.431
Single	83	102		65	69
Multiple	34	17		18	14
Histological differentiation			0.104			0.684
Well	17	27		15	19
Moderate	67	70		50	45
Poor	33	22		18	19
HBsAg			0.332			0.659
Positive	97	104		70	72
Negative	20	15		13	11
AFP (ng/mL)			0.006			0.475
Median	460.3	100		293	255
Range	1–1,21,000	0–1,21,000		1–1,21,000	0–1,21,000

HBsAg, Hepatitis B surface antigen; AFP, α-fetoprotein.